XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
shares in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating activities:      
Net loss $ (47,147,000) $ (36,659,000) $ (39,477,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Share-based compensation 3,928,000 995,000 774,000
Depreciation 5,448,000 4,894,000 4,434,000
Debt related fees and amortization expense 3,921,000 3,401,000 4,666,000
Intangibles and other amortization expense 46,000 48,000 48,000
Accretion and other expenses of Series A preferred units 7,717,000 4,673,000 2,257,000
Gain on debt extinguishment (1,134,000) 0 0
Deferred tax benefit 0 (984,000) 1,123,000
Provision for excess and obsolete inventory 1,040,000 0 0
Provision for bad debts 144,000 1,260,000 0
Change in fair value of stock appreciation rights 0 0 (80,000)
Changes in operating assets and liabilities:      
Accounts receivable 94,000 (1,088,000) (963,000)
Inventories (2,211,000) 2,392,000 (491,000)
Prepaid expenses (4,849,000) 44,000 147,000
Other assets 2,368,000 253,000 (594,000)
Accounts payable (8,000) 1,400,000 1,001,000
Accrued interest expense and fees 14,456,000 21,728,000 18,033,000
Other liabilities 730,000 123,000 7,088,000
Net cash (used in) provided by operating activities (20,647,000) 2,480,000 (2,034,000)
Investing activities:      
Capital expenditures (26,652,000) (19,340,000) (8,578,000)
Grant proceeds received for capital expenditures 3,758,000 2,031,000 0
Net cash used in investing activities (22,894,000) (17,309,000) (8,578,000)
Financing activities:      
Proceeds from borrowings 0 12,648,000 56,314,000
Repayments of borrowings (55,523,000) (15,463,000) (51,878,000)
TEC debt renewal and waiver fee payments (1,108,000) (350,000) (530,000)
Grant proceeds received for capital expenditures 115,000 256,000 1,364,000
Payments on finance leases (505,000) (1,471,000) 0
Proceeds from issuance of common stock in equity offering 103,591,000 5,113,000 0
Proceeds from the exercise of stock options 1,304,000 287,000 0
Proceeds from Series A preferred units financing 3,130,000 13,755,000 4,815,000
Series A preferred financing redemption (300,000)    
Net cash provided by financing activities 50,704,000 14,775,000 10,085,000
Effect of exchange rate changes on cash and cash equivalents (4,000) (10,000) (5,000)
Net change in cash and cash equivalents for period 7,159,000 (64,000) (532,000)
Cash and cash equivalents at beginning of period 592,000 656,000 1,188,000
Cash and cash equivalents at end of period 7,751,000 592,000 656,000
Supplemental disclosures of cash flow information, cash paid:      
Cash paid for interest 5,682,000 1,324,000 2,476,000
Income taxes paid 7,000 8,000 8,000
Supplemental disclosures of cash flow information, non-cash transactions:      
Subordinated debt extension fees added to debt 680,000 680,000 680,000
Fair value of warrants issued to subordinated debt holders $ 1,546,000 181,000 162,000
Fair value of warrants issued for capital expenditures 1,344    
TEC debt extension, waiver fees, promissory notes fees added to debt $ 608,000 1,747,000 1,602,000
Capital expenditures in accounts payable 7,693,000 5,931,000 2,391,000
Operating lease liabilities arising from obtaining right of use assets   2,817,000 1,181,000
Financing lease liabilities arising from obtaining right of use assets 113,000 2,309,000  
Stock Appreciation Rights issued for GAFI Amendment No. 1     $ 1,050,000
Capital expenditures purchased on financing 55,000 $ 5,652,000  
Issuance of equity to pay off accounts payable $ 893